Chemosensitivity of resistant colon cancer cell lines to lobaplatin, heptaplatin, and dicycloplatin

被引：7
作者：
Wei, Wen [1 ,2 ]
Liu, Zhen [1 ]
Chen, Xi [1 ]
Bi, Feng [1 ]
机构：
[1] West China Hosp, Dept Abdominal Oncol, Ctr Canc, Chengdu, Sichuan, Peoples R China
[2] Sichuan Canc Hosp, Dept Chemotherapy, Chengdu, Sichuan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | 2014年 / 52卷 / 08期
基金：
中国国家自然科学基金;
关键词：
chemosensitivity; platinum; drug resistance; colon cancer; COLORECTAL-CANCER; PLATINUM DRUG; ANTITUMOR-ACTIVITY; CLINICAL-TRIAL; PHARMACOKINETICS; CHEMOTHERAPY; ANALOG;
D O I：
10.5414/CP202023
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Purpose: Lobaplatin, heptaplatin, and dicycloplatin are three new platinum drugs. The aim of this study is to investigate the chemosensitivity of resistant colon cancer cell lines to these three drugs. Methods: Eight resistant colon cancer cell lines (four oxaliplatin-resistant colon cancer cell lines and four irinotecan-resistant colon cancer cell lines) were cultured in 96-well plates. Lobaplatin, heptaplatin, and dicycloplatin were added in various concentrations. IC50 was determined by MTT assay and the results were confirmed by CCK-8 assay. A cell death detection ELISA assay was performed to quantitate the apoptotic index by detecting the histone-associated DNA fragments generated by the apoptotic cells. Results: Lobaplatin and heptaplatin had an inhibiting effect in all resistant cell lines, dicycloplatin demonstrate only weak antitumor activity in vitro. Conclusions: We confirmed the efficacy of two platinum drugs to oxaliplatin/irinotecan-resistant colon cancer cell lines, suggesting these two drugs could be considered for improving the control of recurrent colon cancer following initial therapy with oxaliplatin and irinotecan.
引用
收藏
页码：702 / 708
页数：7
相关论文
共 22 条
[1]   Platinum Compounds: A Hope for Future Cancer Chemotherapy [J].
Ali, Imran ;
Wani, Waseem A. ;
Saleem, Kishwar ;
Haque, Ashanul .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (02) :296-306
[2]   Lobaplatin suppresses proliferation and induces apoptosis in the human colorectal carcinoma cell Line LOVO in vitro [J].
Dai, Hong-yu ;
Liu, Lin ;
Qin, Shu-kui ;
He, Xiang-ming ;
Li, Su-yi .
BIOMEDICINE & PHARMACOTHERAPY, 2011, 65 (03) :137-141
[3]   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].
Douillard, JY ;
Cunningham, D ;
Roth, AD ;
Navarro, M ;
James, RD ;
Karasek, P ;
Jandik, P ;
Iveson, T ;
Carmichael, J ;
Alakl, M ;
Gruia, G ;
Awad, L ;
Rougier, P .
LANCET, 2000, 355 (9209) :1041-1047
[4]  
Fink D, 1996, CANCER RES, V56, P4881
[5]   Broadening the clinical use of platinum drug-based chemotherapy with new analogues: satraplatin and picoplatin [J].
Kelland, Lloyd .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (07) :1009-1021
[6]   ANTITUMOR-ACTIVITY OF CIS-MALONATO[(4R,5R)-4,5-BIS(AMINOMETHYL)-2-ISOPROPYL-1,3-DIOXOLANE]PLATINUM(II), A NEW PLATINUM ANALOG, AS AN ANTICANCER AGENT [J].
KIM, DK ;
KIM, HT ;
CHO, YB ;
TAI, JH ;
AHN, JS ;
KIM, TS ;
KIM, KH ;
HONG, WS .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (05) :441-445
[7]   SYNTHESIS AND ANTITUMOR-ACTIVITY OF A SERIES OF [2-SUBSTITUTED-4,5-BIS(AMINOMETHYL)-1,3-DIOXOLANE]PLATINUM(II) COMPLEXES [J].
KIM, DK ;
KIM, G ;
GAM, JS ;
CHO, YB ;
KIM, HT ;
TAI, JH ;
KIM, KH ;
HONG, WS ;
PARK, JG .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (10) :1471-1485
[8]  
Kim HT, 1998, CANCER CHEMOTH PHARM, V41, P109
[9]  
Kim NK, 1999, CANCER, V86, P1109, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1109::AID-CNCR3>3.0.CO
[10]  
2-G
123